(12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh Et Al USOO79100.98B2 (12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh et al. (45) Date of Patent: Mar. 22, 2011 (54) ANT-VEGF ANTIBODES FOREIGN PATENT DOCUMENTS CA 2 O19559 12/1990 (75) Inventors: Germaine Fuh, Pacifica, CA (US); EP O 368 684 9, 2004 Chingwei V. Lee, Foster City, CA (US) WO WO93, 1116.1 6, 1993 WO WO95/27062 10, 1995 WO WO97/.44453 11, 1997 (73) Assignee: Genentech, Inc., South San Francisco, WO WO 97/45450 12/1997 CA (US) WO WO 98.45331 10, 1998 WO WOOO,34337 6, 2000 WO WO 2005/O12359 2, 2005 (*) Notice: Subject to any disclaimer, the term of this WO WO 2005/044853 5, 2005 patent is extended or adjusted under 35 WO WO 2005/123104 12/2005 U.S.C. 154(b) by 32 days. OTHER PUBLICATIONS (21) Appl. No.: 12/315,220 Rudikoffetal, Proc Natl Acad Sci USA 79: 1979-1983, 1982.* Barrios et al. J Molecular Recognition 17: 332-338, 2004.* (22) Filed: Dec. 1, 2008 MacCallum et al., J Mol. Biol 262: 732-745, 1996.* Wu et al., J. Mol. Biol. 294: 151-162, 1999.* Pini et al., “Design and Use of a Phage Display Library: Human (65) Prior Publication Data Antibodies with Subnanomolar Affinity Against a Marker of US 2009/O142343 A1 Jun. 4, 2009 Angiogenesis Eluted From a Two-Dimensional Gel.” J. Biol. Chem. 273:21769-21776 (1998). Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Related U.S. Application Data Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate.” Arch. Ophthalmol. 114: 66-71 (1996). (60) Provisional application No. 60/991,302, filed on Nov. Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of 30, 2007. Patients with Diabetic Retinopathy and Other Retinal Disorders.” N. Engl. J. Med. 331: 1480-1487 (1994). Int. C. Barbas et al., “In vitro Evolution of a Neutralizing Human Antibody (51) to Human Immunodeficiency Virus Type 1 to Enhance Affinity and A 6LX39/395 (2006.01) Broaden Strain Cross-Reactivity.” Proc. Natl. Acad. Sci. USA 91: GOIN33/53 (2006.01) 3809-3813 (1994). CI2P 2L/08 (2006.01) Barbas et al., “Selection and Evolution of High-Affinity Human C07K 6/22 (2006.01) Anti-Viral Antibodies.” Tibtech. 14: 230-234 (1996). Barrios et al., “Length of the Antibody Heavy Chain Complementar (52) U.S. Cl. ............... 424/130.1; 424/133.1; 424/134.1; ity Determining Region 3 as a Specificity-Determining Factor.” J. 424/141.1; 424/142.1; 424/145.1; 435/7.1; Mol. Recongnit. 17: 332-338 (2004). 530/387.1:530/387.3; 530/388.1:530/388.15; Bass et al., “Hormone Phage: An Enrichment Method for Variant 530/388.24; 530/391.3 Proteins with Altered Binding Properties.” Proteins 8: 309-314 (58) Field of Classification Search ........................ None (1990). See application file for complete search history. Beiboer et al., “Guided Selection of a Pan Carcinoma Specific Anti body Reveals Similar Binding Characteristics Yet Structural Diver gence Between the Original Murine Antibody and Its Human Equiva (56) References Cited lent.” J. Mol. Biol. 296: 833-849 (2000). Berkman et al., “Expression of the Vascular Permeability Factor/ U.S. PATENT DOCUMENTS Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms,” J. Clin. Invest. 91: 153-159 (1993). 4,774,378 9, 1988 Faure et al. Borgström et al., “Complete Inhibition of Angiogenisis and Growth 4,816,567 3, 1989 Cabilly et al. of Microtumors by Anti-Vascular Endothelial Growth Factor Neu 5,427,908 6, 1995 Dower et al. tralizing Antibody: Novel Concepts of Angiostatic Therapy from 5.432.018 7, 1995 Dower et al. 5,498,530 3, 1996 Schatz et al. Intravital Videomicroscopy.” Cancer Res. 56: 4032-4039 (1996). 5,580,717 12, 1996 Dower et al. Brekken et al., “Vascular Endothelial Growth Factor as a Marker of 5,658,727 8, 1997 Barbas et al. Tumor Endothelium.” Cancer Res. 58: 1952-1959 (1998). 5,688,666 11, 1997 Bass et al. Brown et al., “Expression of Vascular Permeability Factor (Vascular 5,723,286 3, 1998 Dower et al. Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of 5,733,743 3, 1998 Johnson et al. the Gastrointestinal Tract.” Cancer Res. 53: 4727-4735 (1993). 5,750,373 5, 1998 Garrard et al. Brown et al., “Expression of Vascular Permeability Factor (Vascular 5,821,337 10, 1998 Carter et al. Endothelial Growth Factor) and Its Receptors in Breast Cancer.” 5,837,242 11, 1998 Holliger et al. Hum. Pathol. 26: 86-91 (1995). 5,928,641 7, 1999 Seon et al. 5,969, 108 10, 1999 McCafferty et al. (Continued) 6,054,297 4, 2000 Carter et al. 6,172,197 1, 2001 McCafferty et al. Primary Examiner — Phuong Huynh 6,342,219 1, 2002 Thorpe et al. (74) Attorney, Agent, or Firm — Clark & Elbing LLP 6,416,758 T/2002 Thorpe et al. 6,703,020 3, 2004 Thorpe et al. (57) ABSTRACT 6,884,879 4, 2005 Baca et al. 7,208,582 4, 2007 Rosen et al. The invention herein provides isolated antibodies that bind to 7,691977 4, 2010 Fuh et al. ................... 530,387.1 VEGF. The invention further provides methods of making 2005, 0186208 8, 2005 Fyfe et al. 2006/0280747 12, 2006 Fuh et al. ................... 424,155.1 anti-VEGF antibodies, and polynucleotides encoding anti 2007/002O267 1/2007 Fuh et al. ................... 424,145.1 VEGF antibodies. 2007/O141065 6, 2007 Fuh et al. ................... 424,155.1 2008/024.8033 10, 2008 Ferrara et al. 19 Claims, 11 Drawing Sheets US 7,910,098 B2 Page 2 OTHER PUBLICATIONS Guerrin et al., “Vasculotropin/Vascular Endothelial Growth Factor Is an Autocrine Growth Factor for Human Retinal Pigment Epithelial Carmelietet al., "Abnormal Blood Vessel Development and Lethality Cells Cultured in Vitro.” J. Cell. Physiol. 164: 385-394 (1995). in Embryos Lacking a Single VEGF Allele.” Nature 380: 435-439 "Guidelines for the Management of Rheumatoid Arthritis: 2002 (1996). Update.” Arthritis Rheum. 46: 328-346 (2002). Carmeliet et al., “Angiogenesis in Cancer and Other Diseases.” Hawkins et al., “Selection of Phage Antibodies by Binding Affinity. Nature 407:249-257 (2000). Mimicking Affinity Maturation.” J. Mol. Biol. 226: 889-896 (1992). Carter et al., “High Level of Escherichia coli Expression and Pro Hecht et al., “A Randomized Phase IIIB Trial of Chemotherapy, duction of a Bivalent Humanized Antibody Fragment.” Biotechnol Bevacizumab, and Panitumumab Compared With Chemotherapy and ogy 10: 163-167 (1992). Bevacizumab Alone for Metastatic Colorectal Cancer. J. Clin. Carter et al., “Humanization of an Anti-p185HER2 Antibody for Oncol. 27: 672-680 (2009). Human Cancer Therapy.” Proc. Natl. Acad. Sci. USA 89: 4285-4289 Holliger et al., “Diabodies: Small Bivalent and Bispecific Antibody (1992). Fragments.” Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Hoogenboom et al., “Antibody Phage Display Technology and Its Antibody: Crystal Structure of an Affinity-Matured Fab in Complex Applications.” Immunotechnology 4:1-20 (1998). with Antigen.” J. Mol. Biol. 293:865-881 (1999). Houcket al., “The Vascular Endothelial Growth Factor Family: Iden Chothia et al., “Canonical Structures for the Hypervariable Regions tification of a Fourth Molecular Species and Characterization of of Immunoglobulins,” J. Mol. Biol. 196:901-917 (1987). Alternative Splicing of RNA.” Mol. Endocrinol. 5: 1806-1814 Christinger et al., “Crystallization of the Receptor Binding Domain (1991). of Vascular Endothelial Growth Factor.” Proteins 26: 353-357 Jackson et al., “In Vitro Antibody Maturation: Improvementofa High (1996). Affinity, Neutralizing Antibody Against IL-1 Beta.” J. Immunol. 154: Clackson et al., “Making Antibody Fragments Using Phage Display 3310-3319 (1995). Libraries.” Nature 352: 624-628 (1991). Jones et al., “Replacing the Complementarity-Determining Regions Cunningham et al., “High-Resolution Epitope Mapping of hCGH in a Human Antibody with Those from a Mouse.” Nature 321:522 Receptor Interactions by Alanine-Scanning Mutagenesis.” Science 525 (1986). 244: 1081-1085 (1989). Kanai et al., “Anti-Tumor and Anti-Metastatic Effects of Human de Wildt et al., “Antibody Arrays for High-Throughput Screening of Vascular-Endothelial-Growth-Factor-Neutralizing Antibody on Antibody-Antigen Interactions.” Nat. Biotechnol. 18: 989-994 Human Colon and Gastric Carcinoma Xenotransplanted Orthotopi (2000). cally Into Nude Mice.” Int. J. Cancer 77: 933-936 (1998). Denget al., “Selection of Antibody Single-Chain Variable Fragments Kim et al., “The Vascular Endothelial Growth Factor Proteins: Iden with Improved Carbohydrate Binding by Phage Display,” J. Biol. tification of Biologically Relevant Regions by Neutralizing Chem. 269.9533-9538 (1994). Monoclonal Antibodies.” Growth Factors 7:53-64 (1992). Deshayes et al., “Rapid Identification of Small Binding Motifs with Kim et al., “Inhibition of Vascular Endothelial Growth Factor-In High-Throughput Phage Display: Discovery of Peptidic Antagonists duced Angiogenesis Suppresses Tumour Growth. In Vivo.” Nature of IGF-1 Function.” Chem. Biol. 9: 495-505 (2002). 362: 841-844 (1993). Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Klagsbrun et al., “Regulators of Angiogenesis.” Annu. Rev. Physiol. Growth Factor, Microvascular Hyperpermeability, and 53: 217-239 (1991). Angiogenesis.” Am. J. Pathol. 146: 1029-1039 (1995). Klohs et al., “Antiangiogenic Agents.” Curr. Opin. Biotechnol. 10: Ellis et al., “Surgical Resection. After Downsizing of Colorectal Liver 544-549 (1999). Metastasis in the Era of Bevacizumb. J. Clin. Oncol. 23: 4853-4855 Knappik et al., “Fully Synthetic Human Combinatorial Antibody (2005). Libraries (HuCAL) Based on Modular Consensus Frameworks and Ferrara et al., “Molecular and Biological Properties of the Vascular CDRs Randomized with Trinucleotides. J. Mol. Biol. 296: 57-86 Endothelial Growth Factor Family of Proteins.” Endocr: Rev. 13: (2000). 18-32 (1992). Kobrin et al., “A V Region Mutation in a Phosphocholine-Binding Ferrara et al., “Heterozygous Embryonic Lethality Induced by Tar Monoclonal Antibody Results in Loss of Antigen Binding.” J.
Recommended publications
  • Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Targeting fibrosis in the Duchenne Muscular Dystrophy mice model: an uphill battle 2 Marine Theret1#, Marcela Low1#, Lucas Rempel1, Fang Fang Li1, Lin Wei Tung1, Osvaldo 3 Contreras3,4, Chih-Kai Chang1, Andrew Wu1, Hesham Soliman1,2, Fabio M.V. Rossi1 4 1School of Biomedical Engineering and the Biomedical Research Centre, Department of Medical 5 Genetics, 2222 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada 6 2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Minia 7 University, Minia, Egypt 8 3Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, 9 Darlinghurst, NSW, 2010, Australia 10 4Departamento de Biología Celular y Molecular and Center for Aging and Regeneration (CARE- 11 ChileUC), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 12 Santiago, Chile 13 # Denotes Co-first authorship 14 15 Keywords: drug screening, fibro/adipogenic progenitors, fibrosis, repair, skeletal muscle. 16 Correspondence to: 17 Marine Theret 18 School of Biomedical Engineering and the Biomedical Research Centre 19 University of British Columbia 20 2222 Health Sciences Mall, Vancouver, British Columbia 21 Tel: +1(604) 822 0441 fax: +1(604) 822 7815 22 Email: mtheret@brc.ubc.ca 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • From Celebrex to a Novel Class of Phosphoinositide-Dependent Kinase 1 (Pdk-1) Inhibitors for Androgen-Independent Prostate Caner
    FROM CELEBREX TO A NOVEL CLASS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK-1) INHIBITORS FOR ANDROGEN-INDEPENDENT PROSTATE CANER DISSERTATION Presented in Partial Fulfillment of the requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jiuxiang Zhu, M.S. * * * * * The Ohio State University 2005 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Robert Brueggemeier Advisor Professor Pui-Kai (Tom) Li Graduate Program in Pharmacy Professor Matthew D. Ringel ABSTRACT Celebrex, a nonsteroidal anti-inflammatory drug (NSAID, cyclooxygenase-2 inhibitor), was reported to induce apoptosis in the prostate cancer cell line PC-3 at 50µM. Early research from our laboratory demonstrated that this apoptotic inducing effect was independent of its COX-2 inhibitory activity. Further investigation showed that PDK-1 was a major protein targeted by celebrex in PC-3 cells to induce apoptosis. However, celebrex was very weak in inhibiting PDK-1 with IC50 of 48µM. To improve its potency, two series of analogs were designed and synthesized. In the first series of 24 compounds, the 5-position methylphenyl moiety of celebrex was replaced by various aromatic ring systems to explore the optimal hydrophobic group. OSU02067 (IC50=9µM) with phenanthrene at the 5-position was the best inhibitor among this series and was selected as the lead compound for further modification. Enzyme kinetics study of PDK-1 inhibition by celebrex indicated that it competed with ATP for binding. Docking of OSU02067 into the ATP binding domain of PDK-1 showed that the sulfonamide moiety hydrogen bonded to hinge region residue Ala162.
    [Show full text]
  • Tyrosine Kinase Inhibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts
    BASIC INVESTIGATION Tyrosine Kinase Inhibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts Hong Kyu Kim, MD,* Ji-Young Choi, PhD,† Sang Min Park, PhD,‡ Chang Rae Rho, MD, PhD,§ Kyong Jin Cho, MD, PhD,¶ and Sangmee Ahn Jo, PhD‡k b significantly reduced, but there was no alteration in p53 protein Purpose: Vatalanib is a small-molecule tyrosine kinase inhibitor. levels in HPFs. We investigated the effects of vatalanib on the proliferation and migration of cultured human pterygial fibroblasts (HPFs). Conclusions: These results indicate that vatalanib significantly suppressed the proliferation and migration of HPFs by decreasing Methods: Pterygium tissues were obtained after pterygium exci- vascular endothelial growth factor and transforming growth factor-b. sion surgery and subjected to primary culture. HPFs were treated Vatalanib showed less toxicity than that of MMC. Based on these with vatalanib at various concentrations. Mitomycin C (MMC) was results, vatalanib may potentially serve as a new adjuvant treatment used as a positive control. Cell proliferation and migration assays after pterygium excision surgery. were used to investigate the effects of vatalanib. Cell death was measured using flow cytometry analysis. Western blot analysis was Key Words: tyrosine kinase inhibitor, vatalanib, mitomycin C, performed to identify signaling molecules associated with the pterygium, cell growth response to vatalanib. (Cornea 2017;36:1116–1123) Results: Vatalanib inhibited both proliferation and migration of HPFs in a dose-dependent manner. Cell proliferation was signif- m terygium is one of the most common ocular surface icantly suppressed by vatalanib (10 and 100 M) and MMC diseases. It is characterized by remodeling, proliferation, (0.004% and 0.04%) treatments.
    [Show full text]
  • Prognostic and Predictive Role of Lactate Dehydrogenase 5 ( LDH5) Expression in Colorectal Cancer Patients Treated with PTK787/Z
    Author Manuscript Published OnlineFirst on June 1, 2011; DOI: 10.1158/1078-0432.CCR-10-2918 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Prognostic and predictive role of lactate dehydrogenase 5 ( LDH5) expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) anti- angiogenic therapy. Short title: LDH5 and PTK/ZK in colorectal cancer 1 1 1 Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, 2 3 4 Kevin C. Gatter, Tanja Trarbach Gunnar Folprecht 5 5 6 7 Michael M. Shi , David Lebwohl , Tarja Jalava , Dirk Laurent 8 2 Gerold Meinhardt , Adrian L. Harris For the ‘Tumour and Angiogenesis Research Group’ 1 Departments of Pathology, and Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece Tel/Fax 0030-2551-31522, Email: targ@her.forthnet.gr 2 Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine and Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, OX3 9DS, UK; Tel -44-1865-222457 Fax: -44-1865- 222431 E-mail: aharris.lab@cancer.org.uk 3 University of Essen, West German Cancer Center, Essen, Germany; tanja.trarbach@uk-essen.de 4 University Hospital Dresden, Dresden, Germany; Gunnar.Folprecht@uniklinikum-dresden.de 5 Novartis Pharmaceuticals Co, East Hanover, NJ, USA; michael.shi@novartis.com 6 ; Bayer Schering Pharma Oy, Espoo, Finland tarja.jalava@bayer.fi 7 Bayer Healthcare Pharmaceuticals, Berlin, Germany; dirk.laurent@bayer.com 8 Bayer Healthcare Pharmaceuticals, NJ, USA, gerold.meinhardt@bayer.com Address for correspondence Michael I. Koukourakis, MD Department of Radiotherapy – Oncology Democritus University of Thrace Alexandroupolis 68100, Greece Tel; 25510-74628 Fax: 25510-30329 Email: targ@her.forthnet.gr Downloaded from clincancerres.aacrjournals.org on September 23, 2021.
    [Show full text]
  • Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
    Published OnlineFirst September 20, 2013; DOI: 10.1158/2159-8290.CD-13-0350 RESEARCH ARTICLE Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia Tea Pemovska 1 , Mika Kontro 2 , Bhagwan Yadav 1 , Henrik Edgren 1 , Samuli Eldfors1 , Agnieszka Szwajda 1 , Henrikki Almusa 1 , Maxim M. Bespalov 1 , Pekka Ellonen 1 , Erkki Elonen 2 , Bjørn T. Gjertsen5 , 6 , Riikka Karjalainen 1 , Evgeny Kulesskiy 1 , Sonja Lagström 1 , Anna Lehto 1 , Maija Lepistö1 , Tuija Lundán 3 , Muntasir Mamun Majumder 1 , Jesus M. Lopez Marti 1 , Pirkko Mattila 1 , Astrid Murumägi 1 , Satu Mustjoki 2 , Aino Palva 1 , Alun Parsons 1 , Tero Pirttinen 4 , Maria E. Rämet 4 , Minna Suvela 1 , Laura Turunen 1 , Imre Västrik 1 , Maija Wolf 1 , Jonathan Knowles 1 , Tero Aittokallio 1 , Caroline A. Heckman 1 , Kimmo Porkka 2 , Olli Kallioniemi 1 , and Krister Wennerberg 1 ABSTRACT We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profi ling and ex vivo drug sensitivity and resistance testing (DSRT) of patients’ cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered fi ve major taxonomic drug-response sub- types based on DSRT profi les, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3 -ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,945,572 B2 Chant Et Al
    USOO8945572B2 (12) United States Patent (10) Patent No.: US 8,945,572 B2 Chant et al. (45) Date of Patent: Feb. 3, 2015 (54) METHODS AND COMPOSITIONS FOR THE FOREIGN PATENT DOCUMENTS DAGNOSIS AND TREATMENT OF CANCER WO WO 1999/44062 9, 1999 WO OOf 46343 8, 2000 (75) Inventors: John Chant, Millbrae, CA (US); WO O3,024987 A1 3, 2003 Anthony S. Guerrero, San Francisco, WO 2005/066211 A2 7/2005 CA (US); Peter Haverty, San Francisco, WO WO 2005,115363 12/2005 CA (US); Cynthia Honchell, San WO 2006/110581 A2 10, 2006 Francisco, CA (US); Kenneth Jung, San WO 2007 134210 A2 11/2007 Francisco, CA (US); Thomas Wu, San OTHER PUBLICATIONS Francisco, CA (US) Gura (Science, 1997, 278: 1041-1042).* (73) Assignee: Genentech, Inc., South San Francisco, Kaiser (Science, 2006, 313: 1370).* CA (US) Gura (Science, 1995, 270:575-577).* Tockman et al (Cancer Res., 1992, 52:271 1s-2718s).* (*) Notice: Subject to any disclaimer, the term of this Pritzker (Clinical Chemistry, 2002, 48: 1147-1150).* patent is extended or adjusted under 35 Bai et al. (Cancer Res., 2010, 70: 7630-9).* Otte et al. (European Journal of Clinical Investigation, 2000, 30, U.S.C. 154(b) by 902 days. 222-229).* Yoshino et al. (Oncology Reports 2005, 13: 247-252).* (21) Appl. No.: 12/300,156 Eswarakumar et al., “Cellular signaling by fibroblast growth factor receptors' Cytokine Growth Factor Rev. 16(2): 139-49 (Apr. 2005). (22) PCT Filed: May 11, 2007 Miki et al., “Determination of ligand-binding specificity by alterna tive splicing: two distinct growth factor receptors encoded by a single (86).
    [Show full text]
  • Piperazine Are Toll-Like Receptor 4 Antagonists, Inhibit NF-Κb Activation, and Decrease TNF-Alpha Secretion in Primary Microglia
    Journal Pre-proof Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia Maiju Rinne Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing , Kert Matlik¨ Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Writing - review & editing , Tiina Ahonen Formal analysis; Validation; Writing - review & editing , Fabio Vedovi Conceptualization; Data curation; Formal analysis; Visualization; Roles/Writing - original draft; Writing - review & editing , Giovanni Zappia Conceptualization; Funding acquisition; Supervision; Writing - review & editing , Vaniaˆ M. Moreira Conceptualization; Funding acquisition; Supervision; Writing - review & editing , Jari Yli-Kauhaluoma Conceptualization; Funding acquisition; Project administration; Supervision; Writing - review & editing , Sakari Leino Formal analysis; Investigation; Visualization; Writing - review & editing , Outi Salminen Formal analysis; Investigation; Visualization; Writing - review & editing , Eija Kalso Conceptualization; Funding acquisition; Project administration; Supervision; Writing - review & editing , Mikko Airavaara Conceptualization; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Roles/Writing - original draft; Writing - review &
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - caroline.heckman@helsinki.fi HEIKKI KUUSANMÄKI - heikki.kuusanmaki@helsinki.fi Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (Lactic-Co
    Int. J. Morphol., 35(2):733-739, 2017. Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (lactic-co-glycolic acid) in Tumor Cell Line Resistant to Chemotherapy Inhibición de Angiogénesis y Progresión Tumoral por Inhibidor Selectivo de Ciclooxigenasa-2 Celecoxib Asociado con Ácido (poli láctico co-glicólico) en Línea de Células Tumorales Resistentes a Quimioterapia Ignacio Roa1.2,3; Mario Cantín4†; Cristian Vilos5; Carlos Rosas6 & David Lemus7 ROA, I.; CANTÍN, M.; VILOS, C.; ROSAS, C. & LEMUS, D. Angiogenesis and tumor progression inhibition of cyclooxygenase-2 selective inhibitor celecoxib associated with poly (lactic-co-glycolic acid) in tumor cell line resistant to chemotherapy. Int. J. Morphol., 35(2):733-739, 2017. SUMMARY: Although, antineoplastic therapies have now been developed reduction of tumor progression, it is necessary to find new therapeutic alternatives to suppress angiogenesis. Thus celecoxib (Cx) has been used for its antiangiogenic action in combination with certain polymeric compounds such as poly (lactic co-glycolic acid) (PLGA) acid, which help to improve the bioavailability and avoid effects of long drug administrations. For this purpose we used a murine tumor model induced by mammary adenocarcinoma cells resistant to chemotherapy (TA3-MTXR). CX/PLGA inhibits the microvascular density, VEGF expression and cell proliferation in addition to increased apoptosis (P <0.0001). Cx reduces tumor progression in a concentration of 1000 ppm associated with PLGA,
    [Show full text]
  • Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) As First-Line Treatment of Metastatic Colorectal Cancer: the RESPECT Trial
    Published OnlineFirst March 26, 2013; DOI: 10.1158/1078-0432.CCR-13-0107 Clinical Cancer Cancer Therapy: Clinical Research Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial Josep Tabernero1, Rocio Garcia-Carbonero3, James Cassidy5, Alberto Sobrero8, Eric Van Cutsem9, Claus-Henning Kohne€ 10, Sabine Tejpar9, Oleg Gladkov11, Irina Davidenko12, Ramon Salazar2, Liubov Vladimirova13, Sergey Cheporov14, Olga Burdaeva15, Fernando Rivera4, Leslie Samuel6, Irina Bulavina16, Vanessa Potter7, Yu-Lin Chang17, Nathalie A. Lokker17, and Peter J. O'Dwyer18 Abstract Purpose: This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sor- afenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC). Experimental Design: Patients were randomized to sorafenib (400 mg b.i.d.) or placebo, combined with mFOLFOX6 (oxaliplatin 85 mg/m2; levo-leucovorin 200 mg/m2; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion) every 14 days. Primary endpoint was progression-free survival (PFS). Target sample was 120 events in 180 patients for >85% power (two-sided a ¼ 0.20) to detect an HR ¼ 0.65. Results: Of 198 patients randomized, median PFS for sorafenib plus mFOLFOX6 was 9.1 months versus 8.7 months for placebo plus mFOLFOX6 (HR ¼ 0.88; 95% CI, 0.64–1.23; P ¼ 0.46). There was no difference between treatment arms for overall survival. Subgroup analyses of PFS and overall survival showed no difference between treatment arms by KRAS or BRAF status (mutant and wild type). The most common grade 3/4 adverse events in the sorafenib and placebo arms were neutropenia (48% vs.
    [Show full text]
  • Cardio-Oncology: Basics and Knowing When You Need an Echo
    1/10/2018 Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography Laboratory Northwestern Memorial Hospital Chicago, Illinois President, American Society of Echocardiography No Disclosures • Acknowledgement: Nausheen Akhter, MD, Director of the cardio-oncology program at Northwestern 1 1/10/2018 Introduction • The number of cancer therapies have significantly increased • Cancer survival has improved • A number of cancer therapies have cardiotoxic effects Cardiotoxic Syndromes Associated with Chemo Agents associated with LV Agents associated with dysfunction hypertension • Bevacizumab (Avastin) • Anthracylines • Cisplatin • Mitoxanthrone • IL-2 • Cyclophosphamide • Trastuzumab Agents associated with Other toxic effects • Ifosfamide • Tamponade or endomyocardial • All-trans retinoic acid fibrosis (Busulfan) • Hemorrhagic Myocarditis Agents associated with (Cyclophosphamide) ischemia • Bradycardia (Taxol, Thalidomide) • 5-FU • Raynaud’s (Vinblastine) • Cisplatin • Autonomic neurop (Vincristine) • Capecitabine (Xeloda) • Long QT (Arsenic trioxide) • Pulm fibrosis (Bleo) • IL-2 Yeh et al. Circulation 2004 2 1/10/2018 Angiogenesis Inhibitors • Angiogenesis is a key factor for tumor growth and survival. • Angiogenesis inhibitors have shown to improve outcomes in various malignancies • Tumor growth suppression achieved by: – Direct inhibition of VEGF ligand’s ability to target receptor (bevacizumab, ramucirumab, aflibercept) – Small molecules that inhibit tyrosine kinases (sunitinib, sorafenib, pazopanid, vandetanib, vatalanib, cobazantinib, axitinib, regorafenib) Mechanisms of Action of Angiogenic Inhibitors Maurea N et. J Cardiovasc Med 2016;17(suppl):e-19-e26 3 1/10/2018 Odds ratio for adverse cardiac events due to angiogenesis inhibitors Abdel-Qadir H et al. Cancer Treatment Reviews 20178;53:120-127. J Am Soc Echocardiogr2014;27:911-39.
    [Show full text]
  • The Role of Receptor Tyrosine Kinases in Mediating Glioblastoma Resistance to Radiotherapy and Temozolomide
    The role of receptor tyrosine kinases in mediating glioblastoma resistance to radiotherapy and temozolomide Zammam Areeb ORCID: 0000-0003-1405-6139 Submitted to the University of Melbourne in total fulfilment of the requirements of the degree of Doctor of Philosophy January 2020 The Department of Surgery The Royal Melbourne Hospital The University of Melbourne ABSTRACT Glioblastoma is the most common and aggressive form of malignant glioma. Currently, despite treatment with surgery followed by radiotherapy and the chemotherapeutic agent temozolomide (TMZ), mean patient survival time is approximately 12 months and the 5-year survival rate is close to 0%. A key factor for the dismal prognosis is tumour recurrence post- treatment which is largely due to: 1) the infiltrative nature of glioblastoma rendering complete resection impossible and 2) glioblastoma cell resistance to radio-chemotherapy. In this thesis we aimed to investigate the cellular mechanisms of receptor tyrosine kinases in conferring resistance to therapy. We first performed a literature search and found that almost all studies that advocated for the utility of targeting RTKs in overcoming treatment resistance did not employ both therapeutic agents comprising standard therapy – radiotherapy and TMZ. We next generated an in vitro glioblastoma resistant model via short-term treatment with radiotherapy and TMZ and found that these cells had down-regulated RTK activity in addition to down-regulated protein and gene expression of the commonly altered and studied epidermal growth factor receptor (EGFR) and MET receptor. After generating an in vitro glioblastoma recurrent model via long-term treatment we demonstrated that the surviving sub-population of cells also displayed down-regulated EGFR and MET expression compared to treatment naïve cells.
    [Show full text]